Targeted cancer therapies often face limited efficacy due to low tumor uptake, resistance mechanisms, and high development costs. Meanwhile, molecular radiotherapy (MRT) offers precise tumor targeting with cytotoxic radiation, but few clinical candidates exist. Many oncology teams struggle to bridge the gap between a promising small molecule and a strong radiotherapeutic lead, missing the chance to extend IP, improve outcomes and diversify pipelines.
We have established a proven framework for selecting and assessing cancer drugs with favourable biodistribution and target specificity to become theranostic candidates. Learn how to analyze drug structure, binding affinity, and pharmacokinetic profiles to predict when radiolabelling may be successful.
Next, we’ll explore in vivo validation using multimodal imaging (PET/SPECT, MRI, optical) to guide candidate prioritization. You’ll uncover best practices for measuring biodistribution, dosimetry and early efficacy. Plus, see how integrated CRO partnerships streamline translation, from construct design to IND-ready MRT candidates.
Key Learning Objectives
- Identify repurposing potential: Evaluate existing or new oncology compounds for MRT candidacy via structural, PK and target expression criteria
- Design and radiolabel effectively: Apply chemistry strategies to integrate diagnostic and therapeutic radionuclides into lead molecules without compromising function
- Validate in vivo confidently: Use non-invasive imaging to quantify biodistribution, dosimetry and assess early efficacy with ex vivo, enabling faster, smarter go/no go decisions
- Learn how to best streamline your preclinical program with end-focus first-in-human
Don’t miss this opportunity to acquire a data-driven roadmap for converting your next oncology asset into a radiotherapeutic differentiation factor. Register now to gain practical skills that could unlock a new therapeutic dimension for your program.
